Joseph Joseph, Truong Kelvin, Lo Serigne N, Foo Fiona, Zaman Sarah, Chow Clara K, Smith Annika
Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.
Dermatol Ther (Heidelb). 2024 May;14(5):1337-1348. doi: 10.1007/s13555-024-01154-8. Epub 2024 Apr 25.
Psoriasis is a risk factor for cardiovascular disease. Biologic agents have revolutionised psoriatic skin control. This study aims to assess the change in cardiovascular risk factors in a cohort of patients treated with 1 year of continuous biologic treatment.
A retrospective medical record review was conducted of consecutive patients receiving biologic therapy for chronic plaque psoriasis in a single dermatology centre at a major tertiary hospital in Australia. The effect of biologic therapy on psoriasis was assessed using a psoriasis area severity index (PASI). Cardiovascular risk factors included systolic blood pressure (SBP), diastolic BP (DBP), heart rate (HR) and body mass index (BMI). Measurements at baseline and 1-year follow-up were compared using paired t-tests.
A total of 106 patients were reviewed with a median age of 44 years, and 63% of the patients were male. At baseline, mean BMI was 30 (SD 7), mean SBP was 129 (SD 17), mean DBP was 81 (SD 9) and mean HR was 82 (SD 14). Over 12 months, the PASI was reduced from 17.4 (SD 8.5) to 1.4 (SD 1.7, p < 0.001) indicating skin improvement. There was no significant difference from baseline in SBP (difference 2.3 mmHg, 95% CI - 1.4-5.9), DBP (0.6 mmHg, 95% CI - 1.2-2.5), BMI (difference - 0.1 kg/m, 95% CI - 0.9-0.7) or HR (difference 1.3, 95% CI - 3.9-6.4).
In patients with psoriasis, markers of cardiovascular disease risk did not improve after 1 year of biologic therapy despite significant improvements in psoriasis skin severity.
银屑病是心血管疾病的一个危险因素。生物制剂彻底改变了银屑病皮肤症状的控制情况。本研究旨在评估一组接受1年持续生物治疗的患者心血管危险因素的变化。
对澳大利亚一家大型三级医院的单一皮肤科中心连续接受生物疗法治疗慢性斑块状银屑病的患者进行回顾性病历审查。使用银屑病面积和严重程度指数（PASI）评估生物疗法对银屑病的疗效。心血管危险因素包括收缩压（SBP）、舒张压（DBP）、心率（HR）和体重指数（BMI）。使用配对t检验比较基线和1年随访时的测量值。
共审查了106例患者，中位年龄为44岁，63%的患者为男性。基线时，平均BMI为30（标准差7），平均SBP为129（标准差17），平均DBP为81（标准差9），平均HR为82（标准差14）。在12个月内，PASI从17.4（标准差8.5）降至1.4（标准差1.7，p<0.001），表明皮肤状况改善。SBP（差异2.3 mmHg，95%置信区间-1.4-5.9）、DBP（0.6 mmHg，95%置信区间-1.2-2.5）、BMI（差异-0.1 kg/m，95%置信区间-0.9-0.7）或HR（差异1.3，95%置信区间-3.9-6.4）与基线相比无显著差异。
在银屑病患者中，尽管银屑病皮肤严重程度有显著改善，但生物治疗1年后心血管疾病风险标志物并未改善。
